Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Investing Activities (2016 - 2025)

Angiodynamics (ANGO) has disclosed Cash from Investing Activities for 16 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 17.34% year-over-year to -$1.6 million, compared with a TTM value of -$9.0 million through Nov 2025, down 139.57%, and an annual FY2025 reading of -$10.2 million, down 108.23% over the prior year.
  • Cash from Investing Activities was -$1.6 million for Q4 2025 at Angiodynamics, down from -$1.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $98.4 million in Q3 2023 and bottomed at -$9.1 million in Q2 2021.
  • Average Cash from Investing Activities over 5 years is $3.5 million, with a median of -$2.4 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities plummeted 518.26% in 2021, then surged 2852.85% in 2023.
  • Year by year, Cash from Investing Activities stood at -$3.8 million in 2021, then soared by 35.15% to -$2.5 million in 2022, then grew by 28.17% to -$1.8 million in 2023, then fell by 9.37% to -$2.0 million in 2024, then grew by 17.34% to -$1.6 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ANGO at -$1.6 million in Q4 2025, -$1.6 million in Q3 2025, and -$2.6 million in Q2 2025.